age1, a San Francisco, CA-based venture capital firm investing in the next generation of founder-led longevity biotech companies, officially launched.
The firm, which held an initial closing for $35m, will invest in entrepreneurs advancing new therapeutics, tools, and technologies targeting aging and age-related disease. age1 focuses on founders and companies at the earliest stages of first-money in, pre-seed, and seed funding and is well-capitalized to continue to support companies through later rounds. The firm’s portfolio companies have access to strategic and regulatory guidance from successful founders, the longevity field’s leading experts, and access to an exceptional talent network.
age1’s team has an industry-leading track record and unwavering commitment to the field, having pioneered the first longevity-focused venture capital fund in 2011 and since backed multiple IPOs and acquisitions.
age1 was co-founded by Laura Deming, founder of The Longevity Fund, and Alex Colville, Ph.D. who studied the biology of aging at Stanford and previous biotech investment manager at prestigious family offices. Dr. Colville previously established the biotech investment arm of Starbloom Capital and the philanthropic work of the Amaranth Foundation to advance the field of the biology of aging where he managed more than $100 million in investments and philanthropy. He will lead age1 as the firm’s General Partner.
They had invested in companies including Loyal, Gordian Biotechnology, Fauna Bio, Spring Discovery, Arda Therapeutics, Rubedo Life Sciences, Conception, and Bexorg.
